Connecting Youth and Young Adults to Optimize ART Adherence: YouTHrive Efficacy Trial
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03149757 |
Recruitment Status :
Completed
First Posted : May 11, 2017
Last Update Posted : June 8, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections | Behavioral: YouTHrive Behavioral: Information-only Control | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 205 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Connecting Youth and Young Adults to Optimize ART Adherence: Testing the Efficacy of the Youth Thrive Intervention |
Actual Study Start Date : | May 16, 2017 |
Actual Primary Completion Date : | May 31, 2022 |
Actual Study Completion Date : | May 31, 2022 |
Arm | Intervention/treatment |
---|---|
Experimental: YouTHrive
YouTHrive is a five-month technology-based intervention that uses peer-to-peer interaction, daily self-monitoring, and tailored content to address barriers to HIV medication adherence.
|
Behavioral: YouTHrive
The YT website is a mobile-enhanced private social networking website. Participants on the site are anonymous and choose alternate usernames and personalized profile features for a new online identity within YT. The investigators designed YouTHrive to encourage social support, reduce isolation, improve HIV medication adherence, and promote general well being. The study involves rolling recruitment so that new members are continuously entering the intervention. Participants use YT for five months before "graduating" from the program. The core components of YT are: 1) peer-to-peer interaction in a shared feed; 2) daily monitoring of HIV medication adherence and real-time mood; 3) daily mixed-media content with strategies to improve medication adherence' and 4) goal setting and monitoring.
Other Name: YT |
Active Comparator: Thrive Tips
Participants randomized to the control condition will receive a weekly email with static informational content about living with HIV and general well being.
|
Behavioral: Information-only Control
Participants will receive 21 emails, once per week, for five months. The emails will include static informational content relatable to YLWH, but informational content will not be focused on ART medication adherence. |
- Participants with Self-Reported ART Adherence [ Time Frame: Baseline and 5-month follow-up time points ]The investigators will test the efficacy of the YT intervention to elicit higher self-reported ART adherence among youth living with HIV (YLWH) at the 5-month follow-up time point compared to an HIV information-only control condition. Self-reported ART adherence will be assessed at baseline and 5-months.
- Participants with Viral Load [ Time Frame: Baseline and 5-month follow-up time points ]The investigators will test the efficacy of the YT intervention to suppress viral load (VL) among youth living with HIV (YLWH) at the 5-month follow-up time point compared to an HIV information-only control condition. Viral load will be assessed at baseline and 5-months.
- Participants with HIV Care Attendance [ Time Frame: Baseline and 5-month follow-up time points ]The investigators will test the efficacy of the YT intervention to elicit higher HIV care attendance among youth living with HIV (YLWH) at the 5-month follow-up time point compared to an HIV information-only control condition. HIV care attendance will be assessed at baseline and 5-months.
- Substance-Using Participants with Outcome Measures [ Time Frame: Baseline and 5-month follow-up time points ]Among the YT intervention participants, the investigators will assess whether a different proportion of substance-using youth demonstrate improvement on primary (Outcome 1) and secondary outcomes (Outcomes 2 and 3) at the 5-month follow-up timepoints compared to non-substance using participants.
- Participants with Mental Health and Social Support [ Time Frame: Baseline and 5-month follow-up time points ]Among the YT intervention participants, the investigators will assess whether intervention participants report lower depression and anxiety scores, and higher social support at the 5-month follow-up time point compared to an HIV information-only control condition.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 15 Years to 24 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- 15-24 years of age at the enrollment visit;
- HIV-positive status;
- Residing in Chicago, Houston, NYC, Philadelphia, Atlanta, Tampa, or Raleigh/Durham/Chapel Hill areas and available to meet in-person or virtually with SRV staff for visits at baseline and 5-month follow-up assessment;
- English-speaking (since the intervention will be in English);
- Anticipated continuous internet access and SMS messaging for the intervention period (approximately 5 months);
- Not enrolled in another ART adherence intervention research study at the time of screening;
- Has or is willing to create an e-mail address to use during the study period;
- Did not attend an iTech Youth Advisory Board (YAB) or Youth Advisory Council (YAC) meeting where the YouTHrive study was presented or YouTHrive study materials were discussed.
Exclusion Criteria:
- Is younger than 15 years old or older than 24 years old at the enrollment visit;
- does not have an HIV-positive status;
- Does not reside in Chicago, Houston, NYC, Philadelphia, Atlanta, Tampa, or Raleigh/Durham/Chapel Hill areas and not available to meet with SRV staff for visits at baseline, and 5-month follow-up assessment;
- Does not speak English;
- Does not anticipate having continuous internet access and SMS messaging for the intervention period (approximately 5 months);
- Is enrolled in another ART adherence intervention research study at the time of screening;
- Does not have or is not willing to create an e-mail address to use during the study period;
- Is a member of an iTech Youth Advisory Board (YAB) or Youth Advisory Council (YAC).
Participants who are or become pregnant during the study period will not be excluded.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03149757
United States, Florida | |
University of South Florida | |
Tampa, Florida, United States, 33606 | |
United States, Georgia | |
Emory University | |
Atlanta, Georgia, United States, 30322 | |
United States, Illinois | |
Cook County Hospital and Health Systems CORE Center | |
Chicago, Illinois, United States, 60612 | |
United States, New York | |
Montefiore Children's Hospital | |
Bronx, New York, United States, 10467 | |
United States, North Carolina | |
University of North Carolina at Chapel Hill | |
Chapel Hill, North Carolina, United States, 27514 | |
United States, Pennsylvania | |
Children's Hospital of Philadelphia | |
Philadelphia, Pennsylvania, United States, 19104 | |
United States, Texas | |
Texas Children's Hospital | |
Houston, Texas, United States, 77030 |
Study Chair: | Lisa Hightow-Weidman, PhD | University of North Carolina | |
Study Chair: | Patrick S Sullivan, PhD | Emory University | |
Principal Investigator: | Keith J. Horvath, PhD | University of Minnesota | |
Principal Investigator: | K. Rivet Amico, PhD | University of Michigan |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | University of Minnesota |
ClinicalTrials.gov Identifier: | NCT03149757 |
Other Study ID Numbers: |
16-3136 1U19HD089881 ( U.S. NIH Grant/Contract ) |
First Posted: | May 11, 2017 Key Record Dates |
Last Update Posted: | June 8, 2022 |
Last Verified: | June 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | The investigators will assure the timely release and sharing of data two years after the publication of the main trial findings from the final dataset. Study variables will be available; however, the investigators will protect the rights and privacy of human subjects by redacting all identifiers from the data set. The de-identified data from this project will be available through individual requests directed to the Principal Investigator. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Treatment Adherence Alcohol or Drugs Behavioral Internet |
Adolescents Young Adults Social Support |
HIV Infections Blood-Borne Infections Communicable Diseases Infections Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases |
Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Immunologic Deficiency Syndromes Immune System Diseases |